Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XTX501 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Phase 1 - XTX501 Monotherapy Dose Escalation and Backfill | EXPERIMENTAL | Part 1A will examine XTX501 monotherapy in a Bayesian Optimal Interval design to determine the maximum tolerated dose up to 10 dose regimens. Part 1B will further evaluate the safety and antitumor activity of XTX501 at dose regimens under consideration for the recommended Phase 2 dose(s). |
| Phase 2- XTX501 Monotherapy Dose Expansion in metastatic NSCLC | EXPERIMENTAL | Phase 2 will further evaluate the efficacy of the selected recommended Phase 2 dose(s) in participants with metastatic NSCLC. |
| Name | Type | Description |
|---|---|---|
| XTX501 | DRUG | XTX501 monotherapy |
Inclusion Criteria: * Measurable disease at baseline per RECIST v1.1 * ECOG performance status of 0 or 1 * Adequate organ function * Metastatic NSCLC: * Must have histologically confirmed metastatic NSCLC. * Tumor must have been assessed for EGFR and ALK per local standard of practice; patient...
XTX501 is an investigational small molecule being studied for the treatment of metastatic non-small cell lung cancer (NSCLC) and advanced solid tumors. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
XTX501 targets PD-1, an immune checkpoint protein. By targeting PD-1, the drug is designed to modulate the immune system's response against cancer cells. It is being evaluated in a Phase 1 clinical trial for metastatic NSCLC and advanced solid tumors.
XTX501 is being developed by Xilio Therapeutics, Inc., a biopharmaceutical company. The company is conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with metastatic non-small cell lung cancer and advanced solid tumors.
XTX501 is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is designed to assess the drug's safety, tolerability, and preliminary efficacy.
XTX501 is being evaluated in a Phase 1 clinical trial with the identifier NCT07688577. This trial is studying the drug in patients with metastatic non-small cell lung cancer and advanced solid tumors. The trial is not yet recruiting and aims to enroll approximately 140 participants.
No alternative names for XTX501 have been disclosed. The drug is identified solely by its code name XTX501 in clinical trial registrations and is being developed by Xilio Therapeutics, Inc. for the treatment of metastatic non-small cell lung cancer and advanced solid tumors.